Mifegyne (Mifepristone)

Mifepristone is a competitive antagonist of progesterone receptors. By binding to these receptors in the endometrium, it prevents progesterone from maintaining the pregnancy, causing decidual breakdown and making the uterus more responsive to prostaglandins such as misoprostol, which then induce uterine contractions.

The specific dose and regimen of Mifegyne are determined by the prescribing clinician based on gestational age, local guidelines, and combination with misoprostol. Healthcare providers select the appropriate tablet strength and timing to ensure safety and effectiveness.

Mifegyne is intended for use to terminate an early pregnancy and is not used to treat ongoing pregnancy. It is contraindicated in ongoing pregnancy beyond the approved gestational limit and should not be used while breastfeeding, as safety for the infant has not been established.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mifegyne (mifepristone) is the only progesterone receptor antagonist approved for early medical abortion, offering higher efficacy when combined with misoprostol compared with misoprostol alone. Alternative regimens without mifepristone generally have lower success rates and may require more doses of misoprostol.

Mifegyne tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Mifegyne is taken orally as a single tablet under medical supervision. After ingestion, misoprostol is administered (usually buccally, sublingually, or vaginally) according to the approved protocol to complete the abortion process.

Serious risks include heavy or uncontrolled bleeding, severe infection (sepsis), allergic reactions such as anaphylaxis, liver injury, and, in rare cases, uterine rupture. Patients should be monitored closely and instructed to seek immediate medical attention if they experience severe abdominal pain, excessive bleeding, or signs of infection.

Mifegyne is contraindicated in women with known or suspected ectopic pregnancy, chronic adrenal insufficiency, long‑term corticosteroid therapy, severe anemia, coagulation disorders, or allergy to mifepristone or misoprostol. It should also not be used beyond 10 weeks gestation or in patients with uncontrolled medical conditions that increase procedural risk.